All Oncology News

The OncLive® News page includes the latest in clinical oncology news, including breaking regulatory decisions, clinical trial findings, pivotal and practice-changing data published in academic peer-reviewed journals, and more across solid and hematologic malignancies. Regulatory news includes new drug approvals by the FDA and European Union, priority review and breakthrough therapy designations, and orphan drug and fast track statuses.

High T-Cell Diversity Linked to Better Prognosis in mRCC

January 14th 2016

The VEGFR inhibitor pazopanib was efficacious independent of T-cell receptor–gamma entropy in metastatic renal cell carcinoma setting.

Expert Discusses Emerging Treatments, Immunotherapy Potential in pNETs

January 14th 2016

Pamela L. Kunz, MD, discusses several recent studies that shown promise for the treatment of pancreatic neuroendocrine tumors (NETs), as well as other ongoing trials investigating the potential of immunotherapies in NETs.

The University of Vermont Cancer Center Joins OncLive in Strategic Alliance Partnership

January 13th 2016

OncLive® welcomes the University of Vermont Cancer Center to its Strategic Alliance Partnership for promoting public awareness of the latest advances in cancer research and care.

Onclive Adds The University of Vermont Cancer Center to its Strategic Alliance Partnership

January 13th 2016

New collaboration to publicize advances in cancer research and treatment.

Dramatic Changes on Horizon in Renal Cell Carcinoma

January 12th 2016

The optimal frontline treatment strategy for patients with metastatic renal cell carcinoma could look dramatically different in the next few years, as studies assess combination strategies and predictive biomarkers for immunotherapy and targeted therapies.

Hope Rugo on Pembrolizumab's Potential in ER+/HER2- Breast Cancer

January 12th 2016

Hope Rugo, MD, discusses the phase Ib KEYNOTE-028 trial and the impact of its results thus far, as well as the design, findings, and next steps for the trial.

City of Hope Conference for Clinicians Will Teach Best Practices in Blood Cancers

January 12th 2016

City of Hope is offering an interactive educational conference for oncologists, hematologists and oncology nurses to learn about the latest advances in bone marrow transplants, as well as the treatment of leukemia, lymphoma and myeloma.

FDA Grants Venetoclax Priority Review in Second-Line CLL

January 12th 2016

The FDA has assigned a priority review to venetoclax for use in adults with chronic lymphocytic leukemia, including patients with a 17p deletion, following at least 1 prior therapy.

Atezolizumab/Vemurafenib Combo Shows Clinical Activity in BRAF+ Melanoma

January 12th 2016

The combination of atezolizumab (MPDL3280A) and vemurafenib (Zelboraf) yielded durable responses in patients with previously untreated BRAF V600–mutated metastatic melanoma in an ongoing phase Ib study.

Final USPSTF Guidelines Scale Back Breast Cancer Screening

January 11th 2016

The US Preventive Services Task Force has issued final guidelines that stand by its recommendation that women at average risk of breast cancer should not start routine screenings until they reach age 50 years and that they should then undergo testing every 2 years.

Jason Luke on Significance of Biomarker Development for Immunotherapy in Melanoma

January 7th 2016

Jason J. Luke, MD, discusses potential new methods for determining prognostic markers in melanoma and the challenges of balancing toxicity with efficacy in designing combination regimens.

Nivolumab Continues to Improve Outcomes in Advanced Melanoma

January 6th 2016

Victoria Atkinson, MD, discusses the impact of the phase III CheckMate-066 trial and nivolumab’s future as both a monotherapy and in combination with other therapies.

Expert Discusses Promising Pembrolizumab Triplet in Advanced Myeloma

January 5th 2016

Jesus San Miguel, MD, PhD, discusses a phase I study examining pembrolizumab added to lenalidomide and low-dose dexamethasone in patients with heavily pretreated relapsed/refractory multiple myeloma, while emphasizing the need for further follow-up.

Intermittent Androgen Deprivation With the GnRH Antagonist Degarelix in Men With Biochemical Relapse of Prostate Cancer

January 3rd 2016

Intermittent degarelix administered as described is noninferior to continuous androgen deprivation in maintaining PSA suppression, which indicates that degarelix is a suitable treatment option in men being considered for intermittent androgen ablation.

NYU Expert Examines Emerging Agents in Colorectal Cancer

December 31st 2015

Jennifer Wu, MD, sheds light on TAS-102, as well as some emerging agents likely to play a role in the treatment of patients with colorectal cancer.

Clinical Decision Making in Multiple Myeloma for the Transplant-Eligible Patient–Upfront Transplant Versus Maintenance Therapy

December 31st 2015

With the development of novel therapies, the role and optimal timing of autologous stem cell transplant for the treatment of multiple myeloma have come into question.

American Cancer Society Awards New Research and Training Grant

December 30th 2015

Rutgers Cancer Institute of New Jersey to train the next generation of cancer researchers.

Usmani on Personalized Combination Treatments for Myeloma Management

December 30th 2015

Saad Usmani, MD, discusses newly approved treatments for patients with multiple myeloma, as well as combination therapies currently being investigated in clinical trials.

Expert Discusses Future of Treatment in CRC

December 30th 2015

John L. Marshall, MD, discusses treatment advancements and other ongoing developments in colorectal cancer.

Reardon on Promising Results With Rindopepimut in Brain Cancer

December 30th 2015

David Reardon, MD, discusses the ReACT study and the potential of rindopepimut and other immunotherapy agents for the treatment of patients with brain cancers, specifically glioblastoma.